What happened?
A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy.
As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions.
Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic. The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Hospital chains company Universal Health Services (NYSE:UHS) jumped 10.1%. Is now the time to buy Universal Health Services? Access our full analysis report here, it’s free.
- Hospital chains company Tenet Healthcare (NYSE:THC) jumped 9.2%. Is now the time to buy Tenet Healthcare? Access our full analysis report here, it’s free.
- Therapeutics company Moderna (NASDAQ:MRNA) jumped 8.5%. Is now the time to buy Moderna? Access our full analysis report here, it’s free.
- Therapeutics company Novavax (NASDAQ:NVAX) jumped 7.2%. Is now the time to buy Novavax? Access our full analysis report here, it’s free.
- Surgical equipment & consumables - specialty company Intuitive Surgical (NASDAQ:ISRG) jumped 10.1%. Is now the time to buy Intuitive Surgical? Access our full analysis report here, it’s free.
Zooming in on Universal Health Services (UHS)
Universal Health Services’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. Moves this big are rare for Universal Health Services and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 8 months ago when the stock dropped 10.6% on the news that the company reported mixed fourth-quarter financial results, where current performance fell short of expectations while its future outlook beat them. The hospital management company disclosed adjusted earnings of $5.88 per share on revenue of $4.49 billion, with both figures narrowly missing analyst forecasts.
In contrast to the quarterly miss, the company's financial forecast for the full year of 2026 was a bright spot, with guidance for both revenue and earnings per share coming in ahead of Wall Street's projections. Despite the more positive outlook for the year ahead, investors focused on the immediate results, and the negative reaction to the fourth-quarter performance overshadowed the strong guidance.
Universal Health Services is down 11.9% since the beginning of the year, and at $193.81 per share, it is trading 20.6% below its 52-week high of $244.18 from November 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Universal Health Services’s shares 5 years ago would now be looking at an investment worth $1,536.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.